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LVAD recipients in the REMATCH trial with more than 1000 patient-months of follow-up
received even greater survival and quality-of-life benefits than medically managed counterparts
with 534 patient-months of follow-up. Furthermore, LVAD survival improved over the course
of the trial, suggesting the effect of accumulated experience on outcome.
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We investigated whether the new pericardial substitute (UBE sheet) that consists of 3 layers
could reduce adhesion formation. This sheet produced no adhesions, a less severe epicardial
reaction, and a smaller shrink ratio. These results indicate that the UBE sheet may cause less
adhesion and a less severe inflammatory reaction after cardiac surgery.
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Patients (n  121) were randomized to receive either oral coenzyme Q10 (300 mg/d) or placebo
for 2 weeks before undergoing elective cardiac operations. Coenzyme Q10 therapy increased the
cardiac mitochondrial coenzyme Q10 level, improved mitochondrial efficiency, and increased
myocardial tolerance to hypoxia-reoxygenation stress.
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